All In Biotech

Drug Trial Radar · NCT06148389

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single-ascending Dose, Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics, and Immunogenicity of STSA-1301 Subcutaneous Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Nov 16, 2023

Primary completion

Apr 3, 2024

Study completion Apr 3, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of STSA-1301 Subcutaneous Injection in healthy subjects.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

  • STSA-1301 subcutaneous injectionDrug

    Subjects will receive the administration dose on Day 0 following protocol requirements.

  • PlaceboDrug

    Subjects will receive the administration dose on Day 0 following protocol requirements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-related adverse events as assessed by CTCAE 5.0.Time frame: 50 days
  2. Safety as measured by subject incidence of treatment-emergent clinically significant changes in clinical laboratory safety tests.Time frame: 50 days
  3. Safety as measured by subject incidence of treatment-emergent clinically significant changes in vital signs.Time frame: 50 days
  4. Safety as measured by subject incidence of treatment-emergent clinically significant changes in physical examination.Time frame: 50 days
  5. Safety as measured by subject incidence of treatment-emergent clinically significant changes in Electrocardiogram (ECG).Time frame: 50 days
  6. Maximum plasma concentration (Cmax)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  7. Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  8. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  9. Time of maximum concentration (Tmax)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  10. Elimination half-life (t1/2)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  11. Elimination rate constant of plasma drug concentration in terminal phase (λz)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  12. Last measurable concentration (Clast)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  13. Mean residence time (MRT)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  14. Clearance (CL)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days
  15. Apparent volume of distribution (Vz)Time frame: Pre-dose; after dose 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 14 days, 21 days and 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital,Capital Medical University

    Beijing, Chaoyang District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.